


CLAIMS

1. A compound of formula I:



(I)

wherein:

10 X is C₁₋₆ alkylene or C₂₋₆ alkenylene, each of which is optionally substituted by one or more fluorine atoms;

R is aryl, C₃₋₈ cycloalkyl or C₅₋₈ cycloalkenyl optionally substituted by one or more fluorine atoms.

15

W is N or CZ;

Z is H, or C₁-C₄ alkyl optionally substituted with halogen.

X¹ is H or C₁-C₄ alkyl,

20

Y¹ is:

C₁-C₄ alkyl, optionally substituted by aryl, or by one or more halogen atoms, with the proviso that when Y¹ is methyl, X¹ is not H,


25 or Y¹ is aryl, or a mono or bicyclic non-aromatic carbocyclic or heterocyclic moiety containing up to 10 ring atoms and which can include up to 3 ring heteroatoms, independently selected from N, O and S, which ring moiety is optionally substituted by one or more substituents independently selected from halogen, C₁-C₄ alkoxy and C₁-C₄ alkyl optionally substituted by one or more halogen.

30

“Aryl” is a mono or bicyclic aromatic carbocyclic or heterocyclic moiety containing up to 10 ring atoms, and which can include up to 3 ring heteroatoms, independently selected from N, O and S, which ring moiety is optionally substituted by one or more substituents, independently selected from halogen, C₁-C₄ alkoxy and C₁-C₄ alkyl optionally substituted by
35 halogen.

and the pharmaceutically acceptable salts, solvates (including hydrates) and prodrugs thereof.

2. A compound according to claim 1 wherein the stereochemistry is as defined in formula (1A):



(1A)

3. A compound, salt, solvate or prodrug according to claim 1 or claim 2 wherein X is a linear C₂₋₄ alkylene moiety optionally substituted by one or more fluorine atoms.
4. A compound, salt, solvate or prodrug according to claim 3 wherein X is propylene.
5. A compound, salt, solvate or prodrug according to any preceding claim wherein R is C₃₋₈ cycloalkyl optionally substituted by one or more fluorine atoms.
6. A compound, salt, solvate or prodrug according to claim 5 wherein R is cyclobutyl or cyclohexyl optionally substituted by one or more fluorine atoms.
7. A compound, salt, solvate or prodrug according to claim 6 wherein R is cyclobutyl or cyclohexyl.
8. A compound, salt, solvate or prodrug according to claim 7 wherein R is cyclohexyl.
9. A compound, salt, solvate or prodrug according to any preceding claim wherein W is N, CH or CCH₃.
10. A compound, salt, solvate or prodrug according to claim 9 wherein W is N.
11. A compound, salt, solvate or prodrug according to any preceding claim wherein Y¹ is C₁-C₄ alkyl (optionally substituted by phenyl or by one or more halogen atoms), phenyl (optionally substituted by one or more substituents independently selected from halogen, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with one or more halogen, and which phenyl ring is optionally pyrido-fused), a 5- or 6-membered heterocyclic ring (with one or two ring heteroatoms selected from N, O and S, which heterocyclic ring is optionally substituted by

one or more substituents independently selected from halogen, C₁-C₄ alkoxy, C₁-C₄ alkyl optionally substituted with one or more halogen).

12. A compound, salt, solvate or prodrug according to claim 11 wherein Y¹ is phenyl, 4-methylphenyl, 4-methoxyphenyl, 4-fluorophenyl, 4-isopropylphenyl, 3,4-dimethoxyphenyl, 8-quinoliny, 3,5-dimethyl-4-isoxazolyl, isopropyl, methyl, benzyl or 3-pyridyl.

13. A compound, salt, solvate or prodrug according to claim 12 wherein Y¹ is phenyl, benzyl, 3,4-dimethoxyphenyl, or 3-pyridyl.

10

14. A compound, salt, solvate or prodrug according to claim 13 wherein Y¹ is phenyl.

15. A compound, salt, solvate or prodrug according to any preceding claim wherein X¹ is H or methyl.

15

16. A compound, salt, solvate or prodrug according to claim 15 wherein X¹ is H.

17. A compound, salt, solvate or prodrug of formula (I) according to claim 1 wherein the substituents are as specified in the compounds of the Examples described herein and the salts, solvates and prodrugs thereof.

20

18. A compound according to claim 1 which is selected from:

(3R)-6-Cyclohexyl-N-hydroxy-3-(3-(((phenylsulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl)hexanamide;

25 (3R)-6-Cyclohexyl-N-hydroxy-3-[3-(((4-methylphenyl)sulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl]hexanamide;

(3R)-6-Cyclohexyl-N-hydroxy-3-[3-(((4-methoxyphenyl)sulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl]hexanamide;

30 (3R)-6-Cyclohexyl-3-[3-(((4-fluorophenyl)sulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide;

(3R)-6-Cyclohexyl-N-hydroxy-3-[3-(((4-isopropylphenyl)sulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl]hexanamide;

(3R)-6-Cyclohexyl-3-[3-(((3,4-dimethoxyphenyl)sulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide;

35 (3R)-6-Cyclohexyl-N-hydroxy-3-(3-(((8-quinoliny)sulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl)hexanamide;

(3R)-6-Cyclohexyl-3-[3-(((3,5-dimethyl-4-isoxazolyl)sulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl]-N-hydroxyhexanamide;

40 (3R)-6-Cyclohexyl-N-hydroxy-3-(3-(((isopropylsulfonyl)amino)carbonyl)-1,2,4-oxadiazol-5-yl)hexanamide;

(3R)-6-Cyclohexyl-N-hydroxy-3-(3-([methyl(methylsulfonyl)amino]carbonyl)-1,2,4-oxadiazol-5-yl)hexanamide;

(3R)-6-Cyclohexyl-N-hydroxy-3-(3-([(phenylmethyl)sulfonyl]amino)carbonyl)-1,2,4-oxadiazol-5-yl)hexanamide;

5 (3R)-6-Cyclohexyl-N-hydroxy-3-(3-([(3-pyridylsulfonyl)amino]carbonyl)-1,2,4-oxadiazol-5-yl)hexanamide;

and the salts, solvates and prodrugs thereof.

19. A compound according to any one of claims 1 to 18 including the salts, solvates and
10 prodrugs thereof, for use in medicine.

20. A compound according to any one of claims 1 to 18 including the salts, solvates and prodrugs thereof, for use in the treatment of a PCP mediated condition or disease.

15 21. The use of a compound according to any one of claims 1 to 18 including the salts, solvates and prodrugs thereof, in the manufacture of an antiscarring medicament.

22. The use of a compound according to any one of claims 1 to 18 including the salts, solvates and prodrugs thereof, for the manufacture of a medicament for the treatment of a
20 condition or disease mediated by PCP.

23. A pharmaceutical composition comprising a compound of formula (I), salts thereof, solvates thereof, and/or prodrugs thereof, according to any one of claims 1 to 18 and a pharmaceutically acceptable diluent, carrier or adjuvant.


25

24. A method of treating a condition mediated by PCP comprising administering a therapeutically-effective amount of a compound according to any one of claims 1 to 18 including the salts, solvates and prodrugs thereof.

30 25. A process for making a compound of formula (I) wherein $W = CZ$ and the other substituents are as defined in claim 1 and the description related to the processes, which comprises one or more of steps (a) to (d):


(a) reaction of a compound of formula (V), deprotonated if necessary with a base, with a reagent of formula $X^2SO_2Y^1$, where X^2 is a suitable leaving group, to make a compound of

35 formula (IV);




(b) deprotection of a compound of formula (IV) to make a compound of formula (III);

5



(c) reaction of a compound of formula (III) with coupling agent (such as an alkylhaloformate or carbonyldiimidazole), to form a compound of formula (II) where L¹ is a suitable leaving group;


10



and/or


(d) reaction of a compound of formula (II) with hydroxylamine or a protected derivative thereof to form the hydroxamic acid of formula (I).

15




26. A process for making a compound of formula (I) where W = N, and the other substituents are as defined in claim 1 and the description related to the processes, which comprises one or more of the steps (a) to (d):


- 5 (a) reaction of a compound of formula (XII), deprotonated if necessary with a base, with a reagent of formula $X^2SO_2Y^1$, where X^2 is a suitable leaving group, to make a compound of formula (XI);



- 10 (b) deprotection of a compound of formula (XI) to make a compound of formula (X);




- 15 (c) reaction of a compound of formula (X) with a coupling agent (such as an alkylhaloformate or carbonyldiimidazole), to form a compound of formula (IX) where L^1 is a suitable leaving group;



AND/or

- 20 (d) reaction of a compound of formula (IX) with hydroxylamine or a protected derivative thereof to form a hydroxamic acid of formula (I).



5

27. A compound of formula (II), (III) or (IV) as defined in claim 25.

28. A compound of formula (IX), (X) or (XI) as defined in claim 26.